Letter to Shareholders

11 November 2026: Control Bionics Limited (ASX: CBL) are presenting at the Bell Potter Healthcare Conference, a virtual conference showcasing Australia's best healthcare companies.

The conference will take place virtually on 17, 18, and 19 November from 8:30am – 5:30pm AEDT.

As our valued shareholder, we are delighted to invite you to join us for the virtual conference.

Our presentation will take place on Wednesday, 18 November at 1:00pm AEDT. CEO Jeremy Steele will provide a business update, and discuss growth strategy and near-term catalysts.

If you would like to join, simply register at https://bellpotterevent.com.au/healthcare-2026-ext/.

We hope you can join us.

Yours sincerely,
Control Bionics team

About the Bell Potter Healthcare Conference



About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.